PARTNERSHIP BETWEEN CHEM-X-INFINITY AND OXELTIS
OXELTIS is a French medicinal chemistry oriented service company that has extensive experience in R&D projects, drug discovery and progressing early stage leads toward the next stage of development as potential drug candidates. More specifically, OXELTIS developed an expertise in nucleoside and nucleotide chemistry, in heterocyclic chemistry, in macrocyclic chemistry and in phosphorus chemistry.
Mainly due to the complexity of their chemistry, sugars are hardly used in the design of chemical libraries. This is why CHEM-X-INFINITY is pleased to have signed an agreement with OXELTIS for the design of original nucleoside intermediates that will be used for the synthesis of libraries. The libraries will explore sugar and base analogs to provide molecules with potent activity as antivirals. The molecules could also be used for some GPCR targets. The scaffolds are little described in the literature and are free for patentability.
The partnership is a long term commitment with the objective to develop several thematic libraries using OXELTIS’s chemistry expertise. The first library of antiviral compounds will be released in 2014.